AG
Artal Group Portfolio holdings
AUM
$930M
1-Year Return
3.57%
This Quarter Return
+7.88%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$3.12B
AUM Growth
+$1.44B
(+86%)
Cap. Flow
+$1.36B
Cap. Flow
% of AUM
43.59%
Top 10 Holdings %
Top 10 Hldgs %
70.07%
Holding
139
New
20
Increased
22
Reduced
20
Closed
25
Top Buys
| 1 |
CAVA Group
CAVA
|
$1.31B |
| 2 |
Lexicon Pharmaceuticals
LXRX
|
$63.6M |
| 3 |
SLRN
ACELYRIN
SLRN
|
$38.1M |
| 4 |
MoonLake Immunotherapeutics
MLTX
|
$20.4M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$18.7M |
Top Sells
| 1 |
WW
WW International
WW
|
$61.1M |
| 2 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$15.8M |
| 3 |
Apellis Pharmaceuticals
APLS
|
$15.1M |
| 4 |
Fate Therapeutics
FATE
|
$14.8M |
| 5 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$13.1M |
Sector Composition
| 1 | Healthcare | 56.49% |
| 2 | Consumer Discretionary | 42.78% |
| 3 | Technology | 0.24% |
| 4 | Financials | 0.2% |
| 5 | Real Estate | 0.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
VIGL
26
DELISTED
Vigil Neuroscience
VIGL
| $18M | 0.56% |
1,911,191
-332,161
| -15% | -$3.12M |
|
27
Geron
GERN
$900M
| $17.9M | 0.55% |
5,565,889
| – | – |
|
28
Roivant Sciences
ROIV
$8.84B
| $16.4M | 0.51% |
1,625,000
+1,025,000
| +171% | +$10.3M |
|
29
Generation Bio
GBIO
$40.2M
| $15.5M | 0.48% |
281,419
| – | – |
|
30
Relay Therapeutics
RLAY
$703M
| $15.2M | 0.47% |
1,213,725
-460,018
| -27% | -$5.78M |
|
|
CBIO
31
Crescent Biopharma, Inc. Common Stock
CBIO
$198M
| $14.9M | 0.46% |
85,891
| – | – |
|
|
IMGN
32
DELISTED
Immunogen Inc
IMGN
| $14.4M | 0.45% |
+765,497
| New | +$14.4M |
|
|
OMGA
33
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
| $14.2M | 0.44% |
2,533,045
| – | – |
|
34
Protagonist Therapeutics
PTGX
$3.76B
| $13.8M | 0.43% |
+500,000
| New | +$13.8M |
|
35
Ventyx Biosciences
VTYX
$180M
| $13.4M | 0.42% |
408,519
-127,293
| -24% | -$4.18M |
|
36
Erasca
ERAS
$443M
| $13M | 0.4% |
4,721,194
| – | – |
|
|
ALPN
37
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $12.3M | 0.38% |
1,193,030
| – | – |
|
|
IMA
38
ImageneBio, Inc. Common Stock
IMA
$94.1M
| $12.1M | 0.38% |
154,126
+25,000
| +19% | +$1.97M |
|
39
Foghorn Therapeutics
FHTX
$323M
| $12.1M | 0.38% |
1,720,720
| – | – |
|
40
Viridian Therapeutics
VRDN
$1.51B
| $12M | 0.37% |
504,978
| – | – |
|
41
Replimune Group
REPL
$486M
| $11.6M | 0.36% |
500,000
| – | – |
|
|
AMAM
42
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $11.6M | 0.36% |
702,291
| – | – |
|
43
Danaher
DHR
$144B
| $11.4M | 0.35% |
+53,580
| New | +$11.4M |
|
44
Intellia Therapeutics
NTLA
$1.3B
| $11.3M | 0.35% |
276,077
| – | – |
|
45
Wave Life Sciences
WVE
$1.3B
| $10.4M | 0.32% |
2,870,523
-129,477
| -4% | -$471K |
|
46
Black Diamond Therapeutics
BDTX
$167M
| $10.3M | 0.32% |
2,046,517
+400,000
| +24% | +$2.02M |
|
47
Cartesian Therapeutics
RNAC
$278M
| $10.2M | 0.32% |
304,555
+141,782
| +87% | +$4.76M |
|
48
Mersana Therapeutics
MRSN
$34.5M
| $9.97M | 0.31% |
121,182
+32,550
| +37% | +$2.68M |
|
49
Natera
NTRA
$23.1B
| $9.73M | 0.3% |
200,000
| – | – |
|
50
Aurinia Pharmaceuticals
AUPH
$1.65B
| $9.68M | 0.3% |
1,000,000
| – | – |
|